Pharmacokinetic Interaction of Anaprazole, Amoxicillin and Clarithromycin after Single-Dose Simultaneous Administration and the Effect of Adding Bismuth on Their Pharmacokinetics in Healthy Male Chinese Subjects
- 15 December 2022
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 48 (2) , 121-132
Abstract
Background and Objective Helicobacter pylori-positive ulcers are treated with a proton pump inhibitor (PPI) + two antibiotics with/without bismuth. The objective of this study was to investigate the pharmacokinetic interaction of the novel PPI anaprazole, amoxicillin and clarithromycin with/without bismuth. Methods This single-centre, randomised, open-label phase 1 pharmacokinetic study included healthy Chinese male participants, comprising two cohorts (cohort 1, 4 × 4 crossover design; cohort 2, 2 × 2 crossover design). In cohort 1, 24 participants received four treatment cycles with a different treatment in each cycle; the washout period between cycles was 9 days. Participants were randomly assigned to one of the following four treatment sequences (1:1:1:1): anaprazole sodium enteric-coated tablet 20 mg monotherapy, amoxicillin 1000 mg monotherapy, clarithromycin 500 mg monotherapy, and a three-drug combination (anaprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg). During each treatment cycle, study drugs were administered twice daily for four consecutive days and once in the morning on the fifth day. Cohort 2 participants were administered a single dose of the three-drug combination and a single dose of a four-drug combination (three-drug combination + bismuth 0.6 g) with a washout period of 11 ± 2 days between treatments. Blood samples were collected for pharmacokinetic analysis. Results Twenty-nine of 32 enrolled participants (cohort 1, n = 24; cohort 2, n = 8) completed the study. There were no significant differences in exposure or time to reach maximum concentration (Tmax) between each single drug or the three-drug combination (cohort 1) or between the three- and four-drug combinations (cohort 1) for any of the drugs/metabolites. Conclusions Dose adjustments for individual drugs are not necessary with combined dosing of anaprazole, amoxicillin, clarithromycin and bismuth.Keywords
This publication has 10 references indexed in Scilit:
- Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical TrialFrontiers in Medicine, 2021
- Evidence-based clinical practice guidelines for peptic ulcer disease 2020Journal of Gastroenterology, 2021
- Concomitant Use of Levothyroxine and Proton Pump Inhibitors in Patients with Primary Hypothyroidism: a Systematic ReviewJournal of General Internal Medicine, 2021
- Qualitative and quantitative determination of anaprazole and its major metabolites in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2020
- 25 Years of Proton Pump Inhibitors: A Comprehensive ReviewGut and Liver, 2017
- Optimum duration of regimens for Helicobacter pylori eradicationCochrane Database of Systematic Reviews, 2013
- Epidemiology of Peptic Ulcer Disease: Endoscopic Results of the Systematic Investigation of Gastrointestinal Disease in ChinaAmerican Journal of Gastroenterology, 2010
- Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2006
- Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administrationJournal of Antimicrobial Chemotherapy, 2002
- Proton Pump Inhibitors and Acid‐Related DiseasesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997